Meihua Medical Enters Private Placement with Non-U.S. Buyers
Ticker: MHUAF · Form: 6-K · Filed: Oct 14, 2025 · CIK: 1835615
| Field | Detail |
|---|---|
| Company | Meihua International Medical Technologies Co., Ltd. (MHUAF) |
| Form Type | 6-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0005, $0.38, $15.2 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: private-placement, financing, international
TL;DR
Meihua Medical just did a private placement with foreign buyers, details TBD.
AI Summary
Meihua International Medical Technologies Co., Ltd. announced on October 14, 2025, that it entered into a securities purchase agreement (SPA) with certain "non-U.S. Persons" identified as "Purchasers" for a private placement. Specific details regarding the dollar amounts or the exact date of the SPA's execution were not disclosed in this filing.
Why It Matters
This private placement could provide Meihua International Medical Technologies with new capital, potentially impacting its financial flexibility and future growth initiatives.
Risk Assessment
Risk Level: medium — The filing indicates a private placement with non-U.S. persons, which can sometimes involve less transparency or different regulatory considerations than public offerings.
Key Players & Entities
- Meihua International Medical Technologies Co., Ltd. (company) — Registrant and party to the SPA
- non-U.S. Persons (company) — Identified as Purchasers in the SPA
- October 14, 2025 (date) — Filing date of the 6-K report
FAQ
What is the total value of the securities purchased in the private placement?
The filing does not specify the dollar amount of the securities purchased in the private placement.
Who are the specific "Purchasers" involved in the private placement?
The filing identifies the purchasers only as certain "non-U.S. Persons" and does not name them specifically.
When was the securities purchase agreement (SPA) officially entered into?
While the filing is dated October 14, 2025, it states the company "entered into" the SPA, but the exact execution date is not provided.
What type of securities are being sold in this private placement?
The filing refers to a "securities purchase agreement" but does not specify the class or type of securities involved.
Does this private placement require registration with the SEC?
The filing does not explicitly state whether registration is required, but private placements to non-U.S. persons often fall under exemptions.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-10-14 17:00:01
Key Financial Figures
- $0.0005 — dinary shares of the Company, par value $0.0005 per share (“Shares”), with
- $0.38 — res”), with the purchase price of $0.38 per Share (the “Offering”),
- $15.2 million — Offering”), for gross proceeds of $15.2 million. The Company currently intends to use t
Filing Documents
- ea0260630-6k_meihua.htm (6-K) — 12KB
- ea026063001ex99-1_meihua.htm (EX-99.1) — 250KB
- 0001213900-25-098827.txt ( ) — 263KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission file number 001-41291 Meihua International Medical Technologies Co., Ltd. (Translation of registrant’s name into English) 88 Tongda Road, Touqiao Town Guangling District, Yangzhou, 225000 People’s Republic of China (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Entry into a Private Placement Meihua International Medical Technologies Co., Ltd. (the “Company”) entered into certain securities purchase agreement (the “SPA”) with certain “non-U.S. Persons” (the “Purchasers”) as defined in Regulation S of the Securities Act of 1933, as amended (the “Securities Act”) on October 8, 2025. Pursuant to the SPA, the Company agreed to sell up to an aggregate of 40,000,000 ordinary shares of the Company, par value $0.0005 per share (“Shares”), with the purchase price of $0.38 per Share (the “Offering”), for gross proceeds of $15.2 million. The Company currently intends to use the net proceeds from the Offering for working capital and general corporate purposes. The parties to the SPA have each made customary representations, warranties and covenants, including, among other things, (a) the Purchasers are “non-U.S. Persons” as defined in Regulation S and are acquiring the Shares for the purpose of investment, (b) the absence of any undisclosed material adverse effect, and (c) the absence of legal proceedings that affect the completion of the transaction contemplated by the SPA. The Shares were issued in reliance on the exemption from registration provided by Regulation S under the Securities Act of 1933. The closing of the Offering will be subject to the satisfaction of all of the closing conditions set forth in the SPA. The form of the SPA is filed as Exhibit 99.1, and such document is incorporated herein by reference. The foregoing is only a brief description of the material terms of the SPA, and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibit. Exhibits Exhibit No. Description 99.1 Form of Securities Purchase Agreement 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Meihua International Medical Technologies Co., Ltd. By: /s/ Leyi Lee Name: Leyi Lee Title: Chief Executive Officer Date: October 14, 2025 2